<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870256</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/200/19</org_study_id>
    <nct_id>NCT03870256</nct_id>
  </id_info>
  <brief_title>Oral Tranexamic Acid Plus Sublingual Misoprostol in Atonic Postpartum Hemorrhage</brief_title>
  <official_title>The Effect of Oral Tranexamic Acid Plus, Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of oral tranexamic acid plus, sublingual
      misoprostol in the management of atonic postpartum hemorrhage (PPH) after vaginal delivery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine atony is the main cause of PPH; therefore, active management of the third stage of
      labor has emerged as a most actual tool in its prevention. The previous study in Egypt
      recorded that 88% of deaths from PPH occur within 4 h of delivery. Tranexamic acid (TA) is an
      antifibrinolytic agent that blocks the lysine-binding site of plasminogen to fibrin.
      Accordingly, clot breaks down, fibrinolysis is inhibited, and excessive bleeding is reduced.
      In previous studies, its safety has been confirmed for use in non-pregnant women, with no
      thromboembolic complications. TA is an inexpensive, widely available medicine that has been
      shown to reduce bleeding in surgery and reduce the risk of death in bleeding trauma patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study was a prospective double-blind randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study was a prospective double-blind randomized study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the amount of blood loss</measure>
    <time_frame>6 hours post delivery</time_frame>
    <description>the amount of blood loss by gm calculated by gravimetric methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients loss more than 1000 ml blood</measure>
    <time_frame>24 hours post delivery</time_frame>
    <description>calculate number of patients loss more than 1000 ml blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of uterotonics</measure>
    <time_frame>24 hours post delivery</time_frame>
    <description>number of patients need of uterotonics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>TA plus misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receives 100 mic gm carbetocin IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>Patient receive 600mic gm sublingual misoprostol</description>
    <arm_group_label>TA plus misoprostol</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Patient receive 100 mic gm carbetocin IV</description>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA</intervention_name>
    <description>The patient receives 1gm oral tranexamic acid</description>
    <arm_group_label>TA plus misoprostol</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants had PPH defined as vaginal bleeding&gt;500 ml after vaginal delivery and
             uterine atony confirmed by abdominal palpation.

        Exclusion Criteria:

          -  were gestational age&lt;37 weeks,

          -  genital tract trauma,

          -  coagulation defect,

          -  women with hypertension, preeclampsia, cardiac, renal or liver diseases, epilepsy

          -  known hypersensitivity to carbetocin or oxytocin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All participants had PPH defined as vaginal bleeding&gt;500 ml after vaginal delivery and uterine atony confirmed by abdominal palpation.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f allam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f allam, md</last_name>
    <phone>0102236052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w shady, md</last_name>
    <phone>01092440504</phone>
    <phone_ext>002</phone_ext>
    <email>nahla.elsayed@aswu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AswanUH</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany F Sallam, md</last_name>
      <phone>00201022336052</phone>
      <email>hany.farouk@aswu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla w Shady, md</last_name>
      <phone>00101092440504</phone>
      <email>nahla.elsayed@aswu.ed.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <keyword>Postpartum Hemorrhage</keyword>
  <keyword>vaginal delivery</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

